<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154832">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02064491</url>
  </required_header>
  <id_info>
    <org_study_id>ETAP</org_study_id>
    <secondary_id>2013-002049-13</secondary_id>
    <nct_id>NCT02064491</nct_id>
  </id_info>
  <brief_title>Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC</brief_title>
  <official_title>Erlotinib Treatment Beyond Progression in EGFR Mutant or Patients Who Have Responded EGFR TKI in Stage IIIB/IV NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Finnish Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Finnish Lung Cancer Group</source>
  <oversight_info>
    <authority>Finland: Finnish Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether continuing erlotinib beyond disease
      progression in combination with chemotherapy is beneficial for NSCLC patients who have EGFR
      mutant disease or who have responded to EGFR TKI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II randomised, multicenter study to assess the efficacy and safety of continuing
      erlotinib in addition to chemotherapy versus chemotherapy alone in patients who have EGFR
      mutant or EGFR TKI responsive NSCLC and have progressed on EGFR TKI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival of the whole study population and in the strata 1-2</measure>
    <time_frame>An expected average of 36 weeks after last subject enrolled into our study</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>An expected average of 52 weeks after last subject enrolled into our study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>An expected average of 36 weeks after last subject enrolled into our study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-progression at 9 and 18 weeks</measure>
    <time_frame>18 weeks after date of randomization of a last patient</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity</measure>
    <time_frame>An expected average of 52 weeks after last subject enrolled into our study</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Erlotinib and Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intercalated erlotinib in combination with chemotherapy for four to six cycles followed by continuous erlotinib maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy for four to six cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <arm_group_label>Erlotinib and Chemotherapy</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <arm_group_label>Erlotinib and Chemotherapy</arm_group_label>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Cisplatin, Carboplatin, Docetaxel, Paclitaxel, Pemetrexed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed stage IIIB/IV NSCLC.

          -  Investigator confirmed progression according RECIST 1.1 during EGFR TKI treatment
             within 28  days of the randomization

          -  Activating mutation (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q) in the EGFR
             gene or have had at least partial response with EGFR TKI lasting ≥ 6 months

          -  Performance status: WHO 0-2

          -  Measurable disease according to RECIST 1.1

          -  Patients must be able to comply with study treatments

          -  Women with child-bearing potential and men with reproductive potential must be
             willing to practice acceptable methods of birth control during the study

          -  Neutrophils ≥ 1'000/μl, Platelets ≥ 100'000/μl, Alanine amino transferase  ≤ 2.5 ×
             Upper limit of normal (ULN) (&lt; 5 × ULN if liver metastases), Alkaline phosphatase ≤
             2.5 × ULN (&lt; 5 × ULN if liver metastases), Serum bilirubin  ≤ 1.5 × ULN, Serum
             Creatinine ≤ 1.5 × ULN.

          -  Patient must be able to comply with the protocol

        Exclusion Criteria:

          -  RECIST 1.1 defined disease progression for more than 28 days while on previous EGFR
             TKI treatment.

          -  Patient has been treated with any investigational agent for any indication within 4
             weeks of study treatment.

          -  Patient has history of hypersensitivity or intolerance to erlotinib or gefitinib.

          -  Patient has history of hypersensitivity or intolerance to chemotherapeutic agents
             used in the study.

          -  Patient with symptomatic central nervous system metastases

          -  Patient has known active hepatitis B or C, or HIV infection

          -  Pregnant or breastfeeding.

          -  Patient with uncontrolled undercurrent illness or circumstances that could limit
             compliance with the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jussi P Koivunen, M.D., Ph.D</last_name>
    <phone>35883153789</phone>
    <email>jussi.koivunen@ppshp.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jukka Lojander, M.D., Ph.D</last_name>
      <email>jukka.lojander@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Jukka Lojander, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aija Knuuttila, M.D., Ph.D</last_name>
      <email>aija.knuuttila@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Aija Knuuttila, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jussi P Koivunen, M.D., Ph.D</last_name>
      <email>jussi.koivunen@ppshp.fi</email>
    </contact>
    <investigator>
      <last_name>Jussi P Koivunen, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pori Central Hospital</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matti Pietiläinen, M.D.</last_name>
      <email>matti.pietilainen@satshp.fi</email>
    </contact>
    <investigator>
      <last_name>Matti Pietiläinen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jarkko Ahvonen, M.D.</last_name>
      <email>jarkko.ahvonen@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Jarkko Ahvonen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hopital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taneli Saariaho, M.D., Ph.D</last_name>
      <email>taneli.saariaho@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Taneli Saariaho, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vaasa Central Hospital</name>
      <address>
        <city>Vaasa</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antti Jekunen, M.D., Ph.D</last_name>
      <email>antti.jekunen@vshp.fi</email>
    </contact>
    <investigator>
      <last_name>Antti Jekunen, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>EGFR mutant</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Treatment Beyond Progression</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
